SCHEMBL20796525

SCHEMBL20796525

O=c1c(-c2ccc(Cl)cc2O)c[nH]c2c(-c3ccc(Cl)cc3)c(CN3CCOCC3)nn12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ARF6 P62330 6/20 0.69
▸ MAPT P10636 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ KDM4E B2RXH2 4/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSP90AA1 P07900 2/20 0.40
▸ HSP90AB1 P08238 2/20 0.40
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ GPR55 Q9Y2T6 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ SLC2A1 P11166 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20796519 0.92 ARF6 (0.58) ARF6MAPTTP53KDM4EALDH1A1
SCHEMBL20796483 0.81 ARF6 (1.00) ARF6
SCHEMBL20796503 0.80 ARF6 (0.67) ARF6PSD
SCHEMBL20796522 0.75 ARF6 (0.65) ARF6PSD
SCHEMBL20796214 0.75 ARF6 (0.86) ARF6
SCHEMBL20796524 0.73 ARF6 (0.58) ARF6KDM4EALDH1A1NPC1HTT
SCHEMBL20796643 0.73 ARF6 (0.69) ARF6PSD
SCHEMBL20796502 0.73 ARF6 (0.66) ARF6KDM4EALDH1A1NPC1HTT
SCHEMBL20796528 0.70 ARF6 (0.69) ARF6MAPTHTTMEN1KMT2A
SCHEMBL20796639 0.69 ARF6 (0.67) ARF6PSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11414442-B2 ARF6 inhibitors and related methods NAVIGEN, INC. (US) 2022-08-16 — — US disclosed
US-20210017201-A1 ARF6 INHIBITORS AND RELATED METHODS NAVIGEN, INC. 2021-01-21 — — US disclosed
WO-2019040499-A2 ARF6 INHIBITORS AND RELATED METHODS NAVIGEN, INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017201-A1 ARF6 INHIBITORS AND RELATED METHODS ARF6, ARF1, ARF5 ARF6 1/4885MAPT 3802/4885TP53 2146/4885
US-11414442-B2 ARF6 inhibitors and related methods ARF6, ARF1, ARF5 ARF6 1/4885MAPT 3802/4885TP53 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback